Skip to main content

Advertisement

Fig. 5 | Thrombosis Journal

Fig. 5

From: Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel

Fig. 5

Differential effect of diabetes on active metabolite formation and platelet function between prasugrel and clopidogrel. a, d Plasma active metabolite (AM) levels after the loading dose (LD) of prasugrel (a) or clopidogrel (d) were measured at 0.5 and 3 h after treatment in patients without diabetes (blue bar) and those with diabetes (red bar). Values are means ± SEM. Statistical significance was determined using the Mann–Whitney U test. b, e The vasodilator-stimulated phosphoprotein-platelet reactivity index (VASP-PRI) was measured at the indicated time points after the LD of prasugrel (b) or clopidogrel (e). Blue lines and red lines represent patients without diabetes and those with diabetes, respectively. Values are means ± SEM. Differences in the time course between groups were determined by repeated measures ANOVA. c, f Platelets in platelet-rich plasma obtained at the indicated time points were stimulated with 20 μM adenosine diphosphate (ADP). The absolute change in maximal platelet aggregation after the LD of prasugrel (c) or clopidogrel (f) as assessed by light transmission (base line – an indicated point) was calculated. Blue lines and red lines represent patients without diabetes and those with diabetes, respectively. Values are means ± SEM. Differences in the time course between groups were determined by repeated measures ANOVA

Back to article page